Quick answer
Pramlintide fixes amylin's aggregation problem; cagrilintide adds albumin binding, stretching half-life from ~50 minutes to ~7 days.
- Pramlintide: ~3,950 Da, proline substitutions at 25/28/29, acute designs
- Cagrilintide: lipidated long-acting analog, once-weekly schedule, chronic or combination designs
- Shared target: amylin receptors (CTR + RAMP1–3)
- Bench notes: serum shifts potency of lipidated peptide; verify lots on the CoA page; stock math in the calculator
For laboratory research use only; not for human consumption.
Why amylin needs an analog in the first place
Cagrilintide and pramlintide are both synthetic amylin analogs, but they were engineered a generation apart and solve different research problems. Pramlintide was designed to make amylin usable at all: a soluble, non-aggregating stand-in for a native hormone that otherwise self-destructs in solution. Cagrilintide was designed to make amylin-receptor research last longer, trading pramlintide's minutes-scale pharmacokinetics for a profile measured in days.
Native human amylin (islet amyloid polypeptide) is a 37-amino-acid hormone co-secreted with insulin from pancreatic beta cells. In its unmodified form it aggregates into amyloid fibrils in solution, the same fibril structures found in diabetic islet tissue, which destroys its usefulness as a research tool. Both pramlintide and cagrilintide exist to work around this problem, using related but not identical structural strategies. Background on the longer-acting compound is in the cagrilintide research overview.
Pramlintide: solving aggregation, not duration
Pramlintide carries three proline substitutions at positions 25, 28, and 29, borrowed from rat amylin, which does not aggregate, that break up the beta-sheet stacking responsible for fibril formation. The result is a stable, near-native-affinity amylin analog with a molecular weight around 3,950 Da. What it doesn't solve is duration: plasma half-life is roughly 50 minutes, so sustained receptor engagement in research protocols requires repeated additions or continuous infusion.
Cagrilintide: aggregation fix plus half-life extension
Cagrilintide (AM833) is a long-acting amylin analog that, like pramlintide, avoids the aggregation problem, and adds a fatty-acid moiety that binds reversibly to albumin in plasma, the same half-life-extension strategy used in semaglutide (the two are examined together in cagrilintide plus semaglutide research). Cagrilintide is not simply pramlintide with a lipid attached: its published design draws on sequence elements from amylin and calcitonin-family peptides, and the exact sequence and acyl group should be taken from the certificate for the lot in hand (the cagrilintide product page states that sequence is reported on the certificate of analysis, where published, and lists a molecular formula of C194H308N54O61). The modification stretches the half-life from pramlintide's roughly 50 minutes to approximately a week in published phase 1 pharmacokinetic data, enabling once-weekly schedules in research protocols instead of multiple daily additions.
Side-by-side comparison
| Property | Pramlintide | Cagrilintide |
|---|---|---|
| Generation | First (aggregation fix) | Second (aggregation fix + albumin binding) |
| Molecular weight | About 3,950 Da | About 4,370 Da (formula C194H308N54O61) |
| Half-life | About 50 minutes | About 7 days |
| Schedule in research protocols | Multiple per day or continuous infusion | Once weekly |
| Washout | Hours | Weeks |
| Receptor target | Amylin receptors (CTR/RAMP) | Amylin receptors (CTR/RAMP); also acts at calcitonin receptor |
| Best fit | Acute, tightly washed-out designs | Chronic or combination designs |
What the difference means for study design
- Acute, tightly time-controlled protocols (for example isolating an acute glucagon-suppression or gastric-emptying response) favor pramlintide's short half-life, which allows a clean washout between conditions.
- Chronic or combination protocols, especially anything pairing amylin-receptor signaling with a once-weekly GLP-1 compound, favor cagrilintide, since its interval matches longer-acting comparators and reduces handling frequency.
- Reversibility is the trade-off: pramlintide's effects clear within hours, while cagrilintide's persist for weeks once exposure stops, which has to be factored into crossover designs.
Shared receptor pharmacology
Both compounds act on amylin receptors, heterodimers of the calcitonin receptor (CTR) with RAMP1, RAMP2, or RAMP3, without meaningful cross-activity at GLP-1 or insulin receptors at standard research concentrations. Because the CTR is the common component, activity at the calcitonin receptor itself is a recognized feature of this class, and receptor-selective controls are needed to separate amylin-receptor from calcitonin-receptor effects. Cagrilintide's fatty-acid modification changes its pharmacokinetics more than its receptor family, which is why the two compounds are often described as pharmacologically related but kinetically distinct. Receptor-class background is in GLP-1 receptor agonists in research for the comparator pathway.
Combination research context
Cagrilintide's once-weekly profile has made it the amylin component in combination research alongside semaglutide, studied together as CagriSema in published clinical trial reports, where the two once-weekly compounds are examined on matched schedules to separate amylin-receptor contributions from GLP-1-receptor effects. Pramlintide has also been studied alongside GLP-1 agonists, but its short half-life complicates synchronization with once-weekly comparators; researchers typically resort to continuous infusion for that pairing. For the incretin side of the pairing, see semaglutide vs. tirzepatide.
Albumin binding and lipid chains: practical assay effects
The same feature that gives cagrilintide its duration affects bench work. Albumin binding lowers the free fraction in serum-containing medium, so apparent potency can shift between serum-free and serum-supplemented assays. Lipidated peptides also adsorb more readily to plastic at low concentrations, so low-bind tubes and carrier protein in dilution buffers are common precautions. Pramlintide, lacking a lipid, behaves more like an ordinary peptide in these respects, though it remains sensitive to pH because it is formulated acidic to stay soluble. When comparing the two in one plate, state medium composition, include a vehicle control, and use the same receptor-expressing cell line.
Verifying and handling cagrilintide for the bench
A lipidated peptide of roughly 4.4 kDa needs both HPLC and intact-mass confirmation; see cagrilintide purity testing for the walk-through and HPLC vs. mass spectrometry for why both are required. The V8 product page lists a 10 mg lyophilized vial at ≥98% HPLC purity, and batch records appear on the CoA page. Storage is 2–8 °C, or −20 °C long term, protected from heat, moisture and light. For a 10 mg vial in 2 mL the nominal concentration is 5 mg/mL; the calculator converts between mass, volume and concentration. Sourcing criteria are in where to buy cagrilintide.
Choosing between them: a decision table
The practical choice usually comes down to timescale, schedule matching and how much the assay depends on free peptide concentration. The table below maps common research questions onto the compound whose kinetics fit best.
| Research question | Better-matched compound | Reason |
|---|---|---|
| Acute amylin-receptor response in cells or tissue | Pramlintide | Fast onset and offset; easy washout |
| Repeated-exposure study over days or weeks | Cagrilintide | Fewer handling steps; stable exposure |
| Pairing with a once-weekly GLP-1 analog | Cagrilintide | Matched schedules |
| Crossover design needing full clearance between arms | Pramlintide | Clears within hours |
| Serum-containing assay where free fraction must be known | Pramlintide, or cagrilintide with measured binding | No lipid-mediated albumin binding for pramlintide |
These are design heuristics rather than rules. In every case, the controls that matter most are a vehicle, a receptor-negative cell line or antagonist control, and a documented lot for each compound so that a difference in outcome can be attributed to the molecules and not to differences in purity or net peptide content.
Summary comparison
- Half-life: pramlintide ~50 minutes vs. cagrilintide ~7 days
- Schedule (research use): pramlintide multiple times daily or infusion vs. cagrilintide once weekly
- Structural basis: pramlintide's proline substitutions at 25, 28 and 29; cagrilintide is a distinct lipidated amylin analog
- Receptor target: both act through amylin (CTR/RAMP) receptors with minimal off-target GLP-1 or insulin receptor activity
- Best fit: pramlintide for acute, tightly washed-out designs; cagrilintide for chronic or combination protocols
The cagrilintide research peptide is available for laboratory use.
Frequently asked questions
Are cagrilintide and pramlintide the same molecule with a different tail?
No. Both are amylin analogs designed to avoid aggregation, but cagrilintide is a distinct lipidated sequence with its own design history, not just pramlintide plus a fatty acid. Check the certificate for the lot's exact sequence.
Why is half-life the main practical difference?
About 50 minutes for pramlintide versus about a week for cagrilintide. That decides whether a design needs repeated additions or a weekly schedule, and how long washout takes.
What receptors do they act on?
Amylin receptors: the calcitonin receptor paired with RAMP1, 2 or 3. Cagrilintide also acts at the calcitonin receptor itself.
Which is better for an acute time-course experiment?
Pramlintide, because its effects clear within hours and allow clean washout between conditions.
Why does serum change cagrilintide potency in vitro?
Its fatty-acid chain binds albumin, reducing the free concentration. Report medium composition and compare like with like.
What does CagriSema refer to?
The combination of cagrilintide with semaglutide examined in published clinical trial reports; see cagrilintide plus semaglutide research.
How is a cagrilintide lot verified?
HPLC for purity, intact-mass spectrometry for identity, and a lot-matched certificate on the CoA page.
What size vial does V8 list?
A 10 mg lyophilized vial at ≥98% HPLC purity, per the product page.
Research Use Only. For laboratory research use only; not for human consumption. This article is research education, not usage guidance.
References
- Kruse T, Hansen JL, Dahl K, et al. Development of cagrilintide, a long-acting amylin analogue. J Med Chem 2021;64:11183–11194.
- Understanding HPLC purity (V8 Peptides)
- HPLC vs. mass spectrometry (V8 Peptides)
- How to read a certificate of analysis (V8 Peptides)
- Third-party testing explained (V8 Peptides)
- Cagrilintide research overview (V8 Peptides)
- Cagrilintide research vial (V8 Peptides product page)